Boston Scientific’s Farapulse PFA System Surpasses $1 Billion in Revenue, Transforming Electrophysiology Market

Farapulse, Boston Scientific's pulsed field ablation (PFA) system, generated over $1 billion in revenue in its first year on the market8.

The company's electrophysiology business experienced significant growth, with a 177% year-over-year increase to $527 million in Q3 20242.

Farapulse has driven unprecedented adoption rates and is considered a major growth driver for Boston Scientific5.

The PFA system's efficiency has led to increased overall procedure volumes in electrophysiology5.

Boston Scientific has expanded Farapulse's availability internationally, securing approval in China and expecting approval in Japan in the second half of 20255.

The company's CEO, Mike Mahoney, stated that the electrophysiology business could become "maybe the biggest business in Boston Scientific"5.

Farapulse has attracted new physicians to Boston Scientific's products, with many completely converting to using it for AFib procedures5.

The success of Farapulse has positioned Boston Scientific as a leader in the rapidly growing PFA market, which is considered one of the hottest areas in the medical device industry5.

Sources:

2. https://www.bioworld.com/articles/713398-boston-sci-stuns-with-177-farapulse-driven-increase-in-ep-revenue?v=preview

5. https://www.medtechdive.com/news/boston-scientific-growth-farapulse/722226/

8. https://www.bioworld.com/articles/716827-boston-scis-farapulse-tops-1b-in-2024-bright-prospects-for-2025?v=preview